Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $46.39 Analyst target: $148.00 Upside: 219.03%
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company is headquartered in Daly City, California.
See the full interactive analysis & chart →Informational only — not investment advice.